Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes

NCT04187833 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Metastatic or Unresectable Melanoma

Interventions

DRUG: Nivolumab
DRUG: Talazoparib

Sponsor

Case Comprehensive Cancer Center